NCT05953740View on ClinicalTrials.gov

A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

September 15, 2023

Primary Completion Date

February 15, 2024

Study Completion Date

February 15, 2024

Conditions
Schizophrenia
Interventions
DRUG

MK-5720

IM injection

DRUG

Placebo to MK-5720

Placebo IM Injection matched to MK-5720

DRUG

MK-8189

Oral Tablet

DRUG

Placebo to MK-8189

Placebo oral tablet matched to MK-8189

Trial Locations (4)

33009

Velocity Clinical Research, Hallandale Beach ( Site 0002), Hallandale

33024

Research Centers of America ( Hollywood ) ( Site 0001), Hollywood

91206

California Clinical Trials Medical Group managed by PAREXEL ( Site 0003), Glendale

08053

Hassman Research Institute Marlton Site ( Site 0007), Marlton

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT05953740 - A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001) | Biotech Hunter | Biotech Hunter